RN-1 dihydrochloride NEW
| Price | $42 | $98 | $158 |
| Package | 1mg | 5mg | 10mg |
| Supply Ability: | 10g |
| Update Time: | 2026-05-11 |
Product Details
| Product Name: RN-1 dihydrochloride | CAS No.: 1781835-13-9 |
| Purity: 99.64% | Supply Ability: 10g |
| Release date: 2026/05/11 |
Product Introduction
Bioactivity
| Name | RN-1 dihydrochloride |
| Description | RN-1 dihydrochloride is an effective and selective irreversible inhibitor of lysine-specific demethylase 1 (LSD1, IC50 = 70 nM). |
| In vitro | RN-1 dihydrochloride exhibits selectivity for LSD1 over MAO-A and MAO-B with IC50 values of 0.51 μM and 2.785 μM respectively[3]. |
| In vivo | In sickle cell disease (SCD) mice, RN-1 dihydrochloride (3-10 mg/kg; i.p.) effectively induces fetal hemoglobin (HbF) levels in red blood cells and reduces disease pathology[1]. In C57BL/6 male mice, after administration of RN-1 dihydrochloride (10 mg/kg, i.p.), concentrations are detectable up to 24 h post dose in both plasma and brain tissues. RN-1 dihydrochloride significantly impairs long-term memory, but not short-term memory. The brain/plasma exposure ratio is 88.9[3]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | H2O : 18 mg/mL (39.79 mM), Sonication and heating to 60℃ are recommended. |
| Keywords | sickle | RN-1 Dihydrochloride | RN1 dihydrochloride | RN-1 | RN1 | RN 1 dihydrochloride | RN 1 | MAO-B | MAO-A | LSD1 | irreversible | Inhibitor | inhibit | HistoneDemethylase | Histone Demethylase | hemoglobin | HbF | fetal | disease | cell | brain-penetrant |
| Inhibitors Related | Procaine | Hydralazine hydrochloride | Safinamide | 1,4-Naphthoquinone | 4-Chlorochalcone | Paeonol | Hydroxylamine hydrochloride | Isatin | Allylthiourea | Daminozide | Eicosapentaenoic Acid | Tyramine |
| Related Compound Libraries | Histone Modification Compound Library | Mitochondrial Membrane Protein-Targeted Compound Library | Bioactive Compound Library | Neuronal Signaling Compound Library | Anti-Alzheimer's Disease Compound Library | Epigenetics Compound Library | CNS-Penetrant Compound Library | Post-Translational Modification Compound Library | Inhibitor Library | Mitochondria-Targeted Compound Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $2500.00 |
VIP2Y
|
TargetMol Chemicals Inc.
|
2026-04-21 | |
| $62.00 |
VIP4Y
|
TargetMol Chemicals Inc.
|
2026-06-02 | |
| $1.00 |
VIP6Y
|
RongNa Biotechnology Co.,Ltd
|
2026-06-24 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY